EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rosuvastatin Intervention in Patients with Chronic Hepatitis B (CHB) Expands CD14+ CD16− Classical Monocytes via Aryl Hydrocarbon Receptor (AHR)

Mina Rahmati, Mojtaba Zare Ebrahimabad, Alale Langari, Ali Najafi, Shohreh Taziki, Alireza Norouzi, Mehrdad Teimoorian, Milad Khorasani, Saeed Mohammadi

Immuno · 17.05.2024 · 4 (2) · 159-171

DOI: 10.3390/immuno4020011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immuno, online erschienen am 17.05.2024. Verfasst von Mina Rahmati und 8 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Research and Technology at Golestan University of Medical Sciences, Gorgan, Iran.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis B (CHB) poses treatment challenges, with treatment response and disease outcome often determined by the immune response, particularly mononuclear phagocytes. Monocytes can differentiate into various subpopulations influenced by AHR. Statins, known for inflammation modulation, may impact monocyte function via AHR activation. This study explored rosuvastatin (RSV)’s effects on monocyte subtypes, inflammatory markers, and AHR in CHB patients. Fifteen CHB patients were randomly assigned to receive either 20 mg RSV or a placebo daily for three months. Flow cytometry assessed CD14+ CD16− (classical), CD14+ CD16+ (intermediate), and CD14dim CD16+ (patrolling) monocyte subtypes, along with AHR levels in each subset. ELISA quantified cytokines IL-6, IFN-γ, IL-12, IL-10, TNF-α, TGF-β, and IL-1β. RSV expanded CD14+ CD16− classical and reduced CD14+ CD16+ intermediate monocytes in CHB patients while increasing AHR+ cell percentages in all subsets. RSV treatment upregulated key AHR target genes (Cyp1a1, Cyp1b1, and ARNT), indicating robust AHR signaling activation. It also reduced pro-inflammatory cytokine levels (IL-6, IFNγ, IL-12, TNF-α) and elevated anti-inflammatory cytokines (IL-10, TGF-β). Thus, RSV may modulate the immune response by altering monocyte subtypes in CHB patients via AHR activation.

Förderung

  • Department of Research and Technology at Golestan University of Medical Sciences, Gorgan, Iran

Zitieren

APA

Rahmati, M., Ebrahimabad, M. Z., Langari, A., Najafi, A., Taziki, S., Norouzi, A., Teimoorian, M., Khorasani, M., & Mohammadi, S. (2024). Rosuvastatin Intervention in Patients with Chronic Hepatitis B (CHB) Expands CD14+ CD16− Classical Monocytes via Aryl Hydrocarbon Receptor (AHR). Immuno, 4(2), 159-171. https://doi.org/10.3390/immuno4020011

Vancouver

Rahmati M, Ebrahimabad MZ, Langari A, Najafi A, Taziki S, Norouzi A, et al. Rosuvastatin Intervention in Patients with Chronic Hepatitis B (CHB) Expands CD14+ CD16− Classical Monocytes via Aryl Hydrocarbon Receptor (AHR). Immuno. 2024;4(2):159-171. doi:10.3390/immuno4020011

BibTeX
@article{Rahmati2024,
  author = {Rahmati, Mina and Ebrahimabad, Mojtaba Zare and Langari, Alale and Najafi, Ali and Taziki, Shohreh and Norouzi, Alireza and Teimoorian, Mehrdad and Khorasani, Milad and Mohammadi, Saeed},
  title = {Rosuvastatin Intervention in Patients with Chronic Hepatitis B (CHB) Expands CD14+ CD16− Classical Monocytes via Aryl Hydrocarbon Receptor (AHR)},
  journal = {Immuno},
  year = {2024},
  volume = {4},
  number = {2},
  pages = {159--171},
  doi = {10.3390/immuno4020011}
}
Kostenlos starten →